Royalty Pharma sees FY25 portfolio receipts $2.9B-$3.05B
Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...
Wesco expects FY25 organic sales to grow 2.5%-6.5%
CEO John Engel concluded, “In 2025, we expect organic sales to grow 2.5% to 6.5% and operating margin to expand, as all three business units ...
DRILLING PLANNED FOR EX PEL 91
Newport Exploration Ltd ("Newport" or "the Company") provides an update for licences in the Cooper Basin, Australia, over which the Company has a 2.5% gross overriding royalty ("GOR"). This ...
Spire reports FY25 first quarter results
Spire Inc. (NYSE: SR) today reported results for its fiscal 2025 first quarter ended December 31. Highlights include: ...